Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects

References

• Moore JG, Halberg F. Circadian rhythm of gastric acid secretion in active duodenal ulcer: chronobiological statistical characteristics and comparison of acid secretory and plasma gastrin patterns with healthy subjects and postvagotomy and pyloroplasty patients. Chronobiol Int 1987;4:101-10
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clin Res Ed) 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (Clin Res Ed) 2000;321:412-19
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (London, England: 1979) 2001;101:671-9
   PubMed Web of Science ®Google Scholar
• Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Sheikhi R, Ostgren CJ, et al. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients. J Hypertens 2013;31:1603-10
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
   PubMed Web of Science ®Google Scholar
• Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res 2006;3:159-65
   PubMedGoogle Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug–drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Kim N, Patrick L, Mair S, et al. Absorption, metabolism and excretion of [(14)C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Xenobiotica 2014;44:522-30
   PubMed Web of Science ®Google Scholar
• Lim KS, Kim JR, Choi YJ, et al. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study. Clin Therapeut 2008;30:1817-30
   PubMed Web of Science ®Google Scholar
• Lim KS, Cho JY, Kim BH, et al. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br J Clin Pharmacol 2009;68:883-90
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51-6
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94-9
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Therapeut 2003;73:322-9
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Therapeut 2003;25:2822-35
   PubMed Web of Science ®Google Scholar
• Marino MR, Langenbacher K, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998;38:246-55
   PubMed Web of Science ®Google Scholar
• McIntyre M, MacFadyen RJ, Meredith PA, et al. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996;28:101-6
   PubMed Web of Science ®Google Scholar
• Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005;111:2518-24
   PubMed Web of Science ®Google Scholar
• Navalkar S, Parthasarathy S, Santanam N, et al. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001;37:440-4
   PubMed Web of Science ®Google Scholar
• Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44:874-7
   PubMed Web of Science ®Google Scholar
• Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metabol Dispos 1998;26:408-17
   PubMed Web of Science ®Google Scholar
• Rhee EJ, Lee WY, Yoon KH, et al. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metabol 2010;12:1113-19
   PubMed Web of Science ®Google Scholar
• Yang SJ, Min KW, Gupta SK, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metabol 2013;15:410-16
   PubMed Web of Science ®Google Scholar
• Noh YH, Lim HS, Jin SJ, et al. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug–drug interaction study in healthy male Korean volunteers. Clin Therapeut 2012;34:1182-94
   PubMed Web of Science ®Google Scholar
• Lee D, Roh H, Son H, et al. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study. Clin Ther 2014;36:1171-81
   Google Scholar
• Crestor (label). Available at: http://www1.astrazeneca-us.com/pi/crestor.pdf [Last accessed 1 April 2014]
   Google Scholar
• Aprovel (label). Available at: http://pk.sanofi-aventis.com/products/Aprovel-300mg-new.pdf [Last accessed 1 April 2014]
   Google Scholar
• Shin D, Cho YM, Lee S, et al. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clin Drug Investig. 2014;34:383-93
   Google Scholar
• Cerra M, Luo WL, Li SX, et al. The effects of simvastatin on the pharmacokinetics of sitagliptin. J Population Therapeut Clin Pharmacol 2012;19:e356-60
   PubMedGoogle Scholar
• Scheen AJ. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opinion Drug Metabol Toxicol 2012;8:745-58
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Huettner S, Stahle H, et al. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Therapeut 2010;48:367-74
   PubMed Web of Science ®Google Scholar
• Trabelsi F, Bartunek A, Vlavonou R, et al. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions. Int J Clin Pharmacol Therapeut 2012;50:741-50
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang X, Lan K, et al. Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. Eur J Drug Metabol Pharmacokinet 2009;34:221-7
   PubMed Web of Science ®Google Scholar
• Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Therapeut 2005;78:330-41
   PubMed Web of Science ®Google Scholar
• Choi JH, Lee MG, Cho JY, et al. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Therapeut 2008;83:251-7
   PubMed Web of Science ®Google Scholar
• Constable S, Farrell J, Naisbitt D, et al. Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan. Br J Dermatol 2006;155:491-3
   PubMed Web of Science ®Google Scholar
• Gambini D, Sala F, Gianotti R, et al. Exanthematous reaction to irbesartan. J Eur Acad Dermatol Venereol 2003;17:472-3
   PubMed Web of Science ®Google Scholar